BPC-157
synthetic 15-amino-acid peptide fragment derived from a protein found in gastric juice
Also called: nicotinamide adenine dinucleotide, NAD, beta-NAD
NAD+ is a coenzyme found in every living cell, where it carries electrons in energy metabolism and fuels enzymes such as sirtuins and PARPs. 'Research NAD+' sold in vials is the molecule itself; it is different from oral NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which are sold as dietary supplements and are converted to NAD+ inside the body.
NAD+ has a longevity and 'cellular energy' reputation, helped by the observation that NAD+ levels fall with age, and IV or injectable NAD+ is sold through wellness clinics. In gym culture it gets framed as a recovery and energy tool, mostly on anecdote.
Human evidence: very limited. For injected or IV NAD+ the human data are small pilots and chart reviews focused on blood levels and tolerability, not performance or recovery outcomes; oral NR/NMN have more (still small) randomized trials.
Not prohibited as a substance. Method M2.2 applies: IV infusions and/or injections of more than 100 mL per 12-hour period are prohibited at all times unless received during hospital treatment, surgery or clinical diagnostic investigations.
Low for the substance itself, but a typical clinic IV NAD+ drip is often well over 100 mL, which can be a violation by method without a TUE. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Not an FDA-approved drug. NAD is listed in Category 1 of FDA's interim 503A bulk drug substances list (the list FDA updated May 14, 2026), which means licensed 503A compounding pharmacies may compound it under FDA's interim policy for patient-specific prescriptions. Oral NMN: FDA confirmed on Sept 29, 2025 that NMN is lawful in dietary supplements. NR is sold as a supplement.
As of 2026-10-01.
Not prohibited as a substance. Method M2.2 applies: IV infusions and/or injections of more than 100 mL per 12-hour period are prohibited at all times unless received during hospital treatment, surgery or clinical diagnostic investigations. Low for the substance itself, but a typical clinic IV NAD+ drip is often well over 100 mL, which can be a violation by method without a TUE. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Not an FDA-approved drug. NAD is listed in Category 1 of FDA's interim 503A bulk drug substances list (the list FDA updated May 14, 2026), which means licensed 503A compounding pharmacies may compound it under FDA's interim policy for patient-specific prescriptions. Oral NMN: FDA confirmed on Sept 29, 2025 that NMN is lawful in dietary supplements. NR is sold as a supplement.
Very limited. For injected or IV NAD+ the human data are small pilots and chart reviews focused on blood levels and tolerability, not performance or recovery outcomes; oral NR/NMN have more (still small) randomized trials.
Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.
synthetic 15-amino-acid peptide fragment derived from a protein found in gastric juice
synthetic peptide based on thymosin beta-4, an actin-binding protein found in most cells